Lung Cancer Diagnostic and Screening Market is Estimated to Witness High Growth Owing to Increasing Investments in Development of Noninvasive Diagnostic Techniques
Lung Cancer Diagnostic and Screening Market Lung cancer diagnostic and screening involves identification of abnormalities or cancer in the lungs through various imaging techniques and biomarkers. Computed Tomography (CT) scans and low-dose computed tomography (LDCT) are commonly used for lung cancer screening as they can detect small nodules in the lungs at an early stage. Moreover, advances in genetic biomarkers, molecular testing, and imaging techniques are facilitating noninvasive diagnosis and better screening of lung cancer. The Global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$ 2243.98 Mn in 2023 and is expected to exhibit a CAGR of 42.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: There is significant opportunity for growth in the lung cancer diagnostic and screening market owing to increasing investments by companies as well as governments for development of